EXCLUSIVE 'I've dreamed of this moment': First ever patient gets 'world's most expensive drug' on the NHS - it costs £2.6million per dose
Called Hemgenix, the drug—which costs an estimated £2.6million per patient—was administered yesterday at St Thomas' NHS Foundation Trust in London.
Delivered as a one-off IV drip, it is the only treatment of its kind for haemophilia B.
This is a bleeding disorder where the body doesn't make enough—or any—of a vital protein critical to clotting.
Clotting stops wounds from bleeding, so those with the disorder risk suffering severe and even life-threatening blood loss from even minor injuries.
Patients also run the risk of what are called 'spontaneous bleeds', which can be triggered without a direct injury and even prove deadly if they occur in a vital organ.
Prior to Hemgenix, all haemophilia B patients needed regular weekly injections of an artificial clotting agent to keep their risk of catastrophic injury to a minimum.
The patient, speaking anonymously, was diagnosed with haemophilia B when he was just 18 months old, and said he was now looking forward to a life 'free of worry'.
'I've always had to be more cautious and to plan ahead. There is a level of anxiety in that and being overly cautious has often led to missed opportunities and things I can't do, like contact sports,' he told MailOnline.
'To experience a life free of the worry and to do things that I wouldn't normally do will also be amazing.'
He added: 'Not needing to plan ahead for treatment deliveries or looking up hospitals in foreign destinations when going on holiday, or having to tell people "sorry I can't do that I've got haemophilia", will be something I've always dreamed of.'
Medics and charities have hailed the roll-out of the therapy as a critical milestone for helping those with the condition lead more fulfilling lives.
Dr Pu-Lin Luo, the consultant haematologist at Guy's and St Thomas' who administered the treatment yesterday said it represented an 'exciting' step in treating the condition.
'This is a big step forward in our ability to manage haemophilia B and could change the lives of some of our patients.
'It is also a testament to the advancement of cell and gene therapies in the UK,' she said.
Kate Burt, chief executive of charity The Haemophilia Society, also added: 'Today marks an important milestone not just for this patient, but for all those living with haemophilia B in the UK.'
'The current treatment of lifelong intravenous injections can place a significant burden on those living with haemophilia and it has an impact on broader family, relationships and work.
'The availability of gene therapy for haemophilia B as a one-time infusion will allow those eligible for treatment to expand their horizons and live life to the full, free from the restrictions of regular injections.'
Despite being approved for use on the NHS last year, yesterday's treatment is the first time Hemgenix has been used by the health service.
It's also the first time the drug has been used in the UK outside of a clinical trial.
Hemgenix is the brand name of the drug etranacogene dezaparvovec.
It works by replacing a patient's defective gene—which is incapable of producing the clotting protein—with one that can, eliminating the need for regular injections.
Studies on the gene therapy have shown the protective effect lasts for at least three years, but the hope is it could work for even longer.
There are approximately 2,000 people with haemophilia B in the UK.
Yet only around 260 with 'moderately severe or severe haemophilia B' are currently eligible for Hemgenix on the NHS.
This puts the potential total bill to the taxpayer at about £676million.
MailOnline understands, however, that the NHS acquired the drug at an undisclosed discount, so the actual cost is likely to be less.
Additionally, while the cost of the drug is roughly £2.6million per patient, medics claim the treatment actually saves the NHS money in the long term.
The lifetime cost of providing a patient the alternative weekly clotting injections has been estimated to be £8million.
This sum doesn't include the cost of life-saving interventions and surgeries haemophilia B may also need.
Hemgenix is made by Philadelphia-based pharmaceutical company CSL Behring.
Reacting to the news today the firm's general manager for UK and Ireland, Eduardo Cabas, said: 'This patient receiving etranacogene dezaparvovec is a testament to the collaborative efforts of the haemophilia community, NICE and NHS England to ensure that patients in the UK are able to access this one-time treatment option.'
Hemgenix was initially described as the 'most expensive drug in the world' when it originally came onto the scene in 2022.
However, other drugs—also gene therapies—have since eclipsed it in terms of overall cost.
Like all medications Hemgenix does come with the risk of side effects.
Patients administered the drug take regular liver function tests to ensure the vital organ is functioning correctly.
This is because there is a risk the medication could trigger a potentially dangerous immune response.
These tests are held one a week for the first three months before they are reduced to once a year.
Patient information leaflets distributed with the drug also highlight a potential increased risk of cancer due to the fact it inserts itself into the DNA of cells.
However, clinical studies have—so far—shown no cancers have been caused by Hemgenix use.
Those taking Hemgenix must also use contraceptives like condoms for at least a year following treatment, due to a process called 'shedding'—where the drug can be passed through bodily fluids like semen.
Patients are also forbidden from donating blood for this reason.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
29 minutes ago
- Telegraph
Don't turn new drivers into amateur ambulances
New rules from the DVSA will ensure that new drivers will be tested on their CPR skills in order to get their licence. I would refresh readers on what CPR is, but two-thirds of Britons already know how to perform this first aid function. Yet, new drivers will be forced to undertake testing on the subject in order to do what they took the test for in the first place. To drive. Already, the RAC estimates that the total cost of learning to drive can exceed £2,000. With waiting lists for tests exceeding five months, and an ongoing reform package not expected to take a hold until the summer of next year, these new changes needlessly add extra strains to an already rigorous driving examination. Since 2020, it has been mandatory to undertake first aid and CPR training as part of our school curriculum. In primary school, basic wound dressing and speaking to emergency services is taught, whilst in the secondary stages, rubber mannequins are deployed. Often St John's Ambulance or qualified staff will step in to rigorously teach compressions, breaths, and the Bee Gees (Staying Alive) in classrooms. In extra curricular activities, such as the Scouts, Cadets, or sports teams, first aid courses are also encouraged, or even form part of the participation tests. This is important – heart attacks happen on the pitch and in the pool, and there has been a very successful campaign to deploy 100,000 defibrillators across the UK in recent years, which is equivalent to the number of heart attacks per year. However, we do not know whether adding additional tests for young drivers will do anything to change the status quo to save more lives. Most people injured or killed in a car crash do not suffer from cardiac arrest. Rather it is blunt force trauma, deep lacerations and contusions, and shock that brings passengers, drivers, and pedestrians to the hospital. It is the inadequacies of the health service that is the central problem. Most ambulances still arrive past their targets, putting pressure on drivers to pick up the slack. But CPR, even if performed properly, can only do so much for major incidents. It cannot be incumbent upon drivers to take up the job of paramedics and rush to the nearest mangled car collision and provide the necessary treatment. Indeed, there is additional risk to encouraging young drivers, especially if they're shocked following an accident they've been involved in, to provide CPR. Poorly given CPR could result in battery charges, and could endanger the very person they are trying to resuscitate. Enough news stories about these amateur ambulance drivers and headlines of litigations, it may put even the most CPR-qualified drivers off leaping into the fray. If the Government wants to get serious about preventing driving accidents, they must start with the quality of our roads. Highways maintenance will only rise by £200m by the end of this Parliament, far short of what is required to fix the potted pavements and decaying road-signs that blight our tarmac. Likewise, the consideration should be given to the Government's continual pressure towards heavier electric vehicles (which are on average 400kg heavier than their hydrocarbon counterparts). These monstering hulks, which tear up our roads, and collide with more force, will do more damage to a driver or pedestrian than CPR could possible hope to recover.
Rhyl Journal
2 hours ago
- Rhyl Journal
‘Contradiction' in figures makes health experts question NHS data
Experts suggest that more patients are being referred for treatment than leaving the waiting list, despite the overall waiting list coming down. Analysis found that in May, for every 100 referrals for pre-planned care, only 86 patient 'pathways' were complete – a scenario that would expect to see the waiting list getting bigger. But the official figures for May, published last month, show that the waiting list for routine hospital treatment in England had dropped to its lowest level for more than two years. 'There appears to be a contradiction in the data,' analysts from the Nuffield Trust think tank said. Writing a piece for part of the Quality Watch programme, the experts claim that an increase in NHS activity alone has not been enough to cause the reduction in the waiting list. Their new report examines so-called 'unreported removals', which occur when someone is taken off the waiting list for a reason other than that person having received their treatment that month. The report says that over the last two financial years there has been an average of 244,500 unreported removals a month. Though the waiting list has started to go down, unreported removals have gone up, they add. Officials from the Department and Health and Social Care insist that over the last 12 months, the number and percentage of unreported removals are lower than 2019. The new report points out that some of these unreported removals will represent patients that did get treatment but it was not recorded properly at the time. Another issue could be problems with NHS software and data management processes. The authors of the review wrote: 'Improving the data quality of waiting lists is important to ensure that people who should not be on the list, like people who have been treated privately or left the country, are no longer counted among those waiting to be seen. 'However, accusations of gaming the validation process, by removing referrals from the waiting list inappropriately without treatment, are likely to persist in the absence of transparency about what actions the unreported removals materially represent. 'The NHS is delivering more planned care, but still not enough to keep up with demand. 'The planned care that is reported is not enough to explain the reduction in the elective waiting list, and the publicly available data provides little more insight.' Officials estimate that 85% of the reduction in the waiting list is because of increased NHS 'activity' and suggest that 15% is because of unreported removals. According to the latest NHS figures, an estimated 7.36 million treatments were waiting to be carried out at the end of May, relating to just under 6.23 million patients, down from 7.39 million treatments and just over 6.23 million patients at the end of April. These are the lowest totals since March 2023 for treatments and April 2023 for patients. The list hit a record high in September 2023, with 7.77 million treatments and 6.50 million patients. The size of the list had been on an upward trend for much of the last 10 years, passing three million treatments in 2014, four million in 2017, five million in 2021 and seven million in 2022. In February 2020, the last full month before the start of the Covid-19 pandemic, the list stood at 4.57 million treatments. The authors of the latest review add: 'The information available in the public domain is insufficient for independent scrutiny of the elective waiting list, and consequently for holding government to account. 'Removals from the waiting list should be described in publicly available data in a meaningful way; the current process is unduly obscure. 'Until more transparent reporting is provided, accountability around unreported removals remains impossible and the planned care waiting list will continue to be a misleading indicator of how the NHS is dealing with demand.' It comes as the NHS in England is to reveal its latest waiting list figures on Thursday. Commenting on the analysis, an NHS England spokesperson said: 'NHS staff have made significant progress in reducing waiting lists in the last year – down by more than 260,000 since June 2024 – and this is driven by the fact that 2,300 more patients are receiving treatment every day compared to last year.' 'While the validation process has a small impact on the overall waiting list – as is made crystal clear in our published monthly waiting list data – it's right we regularly clinically review those waiting so hospitals can prioritise patients more accurately and deploy their resources efficiently.' A Department of Health and Social Care spokesperson added: 'Our drive to clear the huge waiting list backlog we inherited includes making sure all patients are getting the right treatment as quickly as possible. 'That's why we are supporting GPs to seek specialist advice before making referrals, and screening existing waiting lists to check that all patients need to be on there – freeing up capacity to get more people seen more quickly. 'This is one element of our wider work to cut waiting times for patients and improve productivity through our Plan for Change, through which we have already delivered over four million extra appointments and cut the waiting list by 260,000.'
Leader Live
2 hours ago
- Leader Live
‘Contradiction' in figures makes health experts question NHS data
Experts suggest that more patients are being referred for treatment than leaving the waiting list, despite the overall waiting list coming down. Analysis found that in May, for every 100 referrals for pre-planned care, only 86 patient 'pathways' were complete – a scenario that would expect to see the waiting list getting bigger. But the official figures for May, published last month, show that the waiting list for routine hospital treatment in England had dropped to its lowest level for more than two years. 'There appears to be a contradiction in the data,' analysts from the Nuffield Trust think tank said. Writing a piece for part of the Quality Watch programme, the experts claim that an increase in NHS activity alone has not been enough to cause the reduction in the waiting list. Their new report examines so-called 'unreported removals', which occur when someone is taken off the waiting list for a reason other than that person having received their treatment that month. The report says that over the last two financial years there has been an average of 244,500 unreported removals a month. Though the waiting list has started to go down, unreported removals have gone up, they add. Officials from the Department and Health and Social Care insist that over the last 12 months, the number and percentage of unreported removals are lower than 2019. The new report points out that some of these unreported removals will represent patients that did get treatment but it was not recorded properly at the time. Another issue could be problems with NHS software and data management processes. The authors of the review wrote: 'Improving the data quality of waiting lists is important to ensure that people who should not be on the list, like people who have been treated privately or left the country, are no longer counted among those waiting to be seen. 'However, accusations of gaming the validation process, by removing referrals from the waiting list inappropriately without treatment, are likely to persist in the absence of transparency about what actions the unreported removals materially represent. 'The NHS is delivering more planned care, but still not enough to keep up with demand. 'The planned care that is reported is not enough to explain the reduction in the elective waiting list, and the publicly available data provides little more insight.' Officials estimate that 85% of the reduction in the waiting list is because of increased NHS 'activity' and suggest that 15% is because of unreported removals. According to the latest NHS figures, an estimated 7.36 million treatments were waiting to be carried out at the end of May, relating to just under 6.23 million patients, down from 7.39 million treatments and just over 6.23 million patients at the end of April. These are the lowest totals since March 2023 for treatments and April 2023 for patients. The list hit a record high in September 2023, with 7.77 million treatments and 6.50 million patients. The size of the list had been on an upward trend for much of the last 10 years, passing three million treatments in 2014, four million in 2017, five million in 2021 and seven million in 2022. In February 2020, the last full month before the start of the Covid-19 pandemic, the list stood at 4.57 million treatments. The authors of the latest review add: 'The information available in the public domain is insufficient for independent scrutiny of the elective waiting list, and consequently for holding government to account. 'Removals from the waiting list should be described in publicly available data in a meaningful way; the current process is unduly obscure. 'Until more transparent reporting is provided, accountability around unreported removals remains impossible and the planned care waiting list will continue to be a misleading indicator of how the NHS is dealing with demand.' It comes as the NHS in England is to reveal its latest waiting list figures on Thursday. Commenting on the analysis, an NHS England spokesperson said: 'NHS staff have made significant progress in reducing waiting lists in the last year – down by more than 260,000 since June 2024 – and this is driven by the fact that 2,300 more patients are receiving treatment every day compared to last year.' 'While the validation process has a small impact on the overall waiting list – as is made crystal clear in our published monthly waiting list data – it's right we regularly clinically review those waiting so hospitals can prioritise patients more accurately and deploy their resources efficiently.' A Department of Health and Social Care spokesperson added: 'Our drive to clear the huge waiting list backlog we inherited includes making sure all patients are getting the right treatment as quickly as possible. 'That's why we are supporting GPs to seek specialist advice before making referrals, and screening existing waiting lists to check that all patients need to be on there – freeing up capacity to get more people seen more quickly. 'This is one element of our wider work to cut waiting times for patients and improve productivity through our Plan for Change, through which we have already delivered over four million extra appointments and cut the waiting list by 260,000.'
